Skip to content
Brexit’s lasting damage is looking inescapable

Brexit’s lasting damage is looking inescapable

For most of this century, the UK was the biggest beneficiary among the 27 countries in the EU. Measured by gross domestic product, GDP per capita growth, unemployment and superior debt, equity and currency valuations, Britain was the perennial leader. Now on all these, the situation has reversed and the UK is trailing

Read More

​ For most of this century, the UK was the biggest beneficiary among the 27 countries in the EU. Measured by gross domestic product, GDP per capita growth, unemployment and superior debt, equity and currency valuations, Britain was the perennial leader. Now on all these, the situation has reversed and the UK is trailing For most of this century, the UK was the biggest beneficiary among the 27 countries in the EU. Measured by gross domestic product, GDP per capita growth, unemployment and superior debt, equity and currency valuations, Britain was the perennial leader. Now on all these, the situation has reversed and the UK is trailing  Moneycontrol Latest News Read More  

For most of this century, the UK was the biggest beneficiary among the 27 countries in the EU. Measured by gross domestic product, GDP per capita growth, unemployment and superior debt, equity and currency valuations, Britain was the perennial leader. Now on all these, the situation has reversed and the UK is trailing

How a govt healthcare scheme is boosting pharma revenues

How a govt healthcare scheme is boosting pharma revenues

Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system

Read More

​ Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system  Moneycontrol Latest News Read More  

Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system

How a govt healthcare scheme is boosting pharma revenues

How a govt healthcare scheme is boosting pharma revenues

Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system

Read More

​ Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system  Moneycontrol Latest News Read More  

Jan Aushadhi Kendras procure medicines from private manufacturers and public sector drug manufacturers through an open tender system

Moneycontrol Pro Panorama | Mergers are not a please-all solution

Moneycontrol Pro Panorama | Mergers are not a please-all solution

In this edition of Moneycontrol Pro Panorama: IT stocks still a favourite despite earnings cut, learn to predict market price reversals to stay ahead, impact of recent tyre price cut explained, Trump#39;s tantrums a sign of what#39;s to come, and more

Read More

​ In this edition of Moneycontrol Pro Panorama: IT stocks still a favourite despite earnings cut, learn to predict market price reversals to stay ahead, impact of recent tyre price cut explained, Trump#39;s tantrums a sign of what#39;s to come, and more In this edition of Moneycontrol Pro Panorama: IT stocks still a favourite despite earnings cut, learn to predict market price reversals to stay ahead, impact of recent tyre price cut explained, Trump#39;s tantrums a sign of what#39;s to come, and more  Moneycontrol Latest News Read More  

In this edition of Moneycontrol Pro Panorama: IT stocks still a favourite despite earnings cut, learn to predict market price reversals to stay ahead, impact of recent tyre price cut explained, Trump#39;s tantrums a sign of what#39;s to come, and more

Devara Part 1: Man of Masses NTR Jr heads to Goa to begin new shoot schedule for the magnum opus

Devara Part 1: Man of Masses NTR Jr heads to Goa to begin new shoot schedule for the magnum opus

After a hectic schedule in Hyderabad, NTR Jr is now in Goa and has commenced the next shoot schedule of the film Devara today; this leg of the shooting includes filming a song. Devara will be released in two parts.

Read More

​ After a hectic schedule in Hyderabad, NTR Jr is now in Goa and has commenced the next shoot schedule of the film Devara today; this leg of the shooting includes filming a song. Devara will be released in two parts. After a hectic schedule in Hyderabad, NTR Jr is now in Goa and has commenced the next shoot schedule of the film Devara today; this leg of the shooting includes filming a song. Devara will be released in two parts.  Moneycontrol Latest News Read More  

After a hectic schedule in Hyderabad, NTR Jr is now in Goa and has commenced the next shoot schedule of the film Devara today; this leg of the shooting includes filming a song. Devara will be released in two parts.

Buy Pitti Engineering; target of Rs 1083: KR Choksey

Buy Pitti Engineering; target of Rs 1083: KR Choksey

KR Choksey is bullish on Pitti Engineering has recommended buy rating on the stock with a target price of Rs 1083 in its research report dated March 18, 2024.

Read More

​ KR Choksey is bullish on Pitti Engineering has recommended buy rating on the stock with a target price of Rs 1083 in its research report dated March 18, 2024. KR Choksey is bullish on Pitti Engineering has recommended buy rating on the stock with a target price of Rs 1083 in its research report dated March 18, 2024.  Moneycontrol Latest News Read More  

KR Choksey is bullish on Pitti Engineering has recommended buy rating on the stock with a target price of Rs 1083 in its research report dated March 18, 2024.

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.

Read More

​ The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.  Moneycontrol Latest News Read More  

The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.

Local production of EVs a work in progress: Audi India Head

Local production of EVs a work in progress: Audi India Head

The automaker currently imports its entire EV range comprising Q8 50 e-tron, Q8 55 e-tron, Q8 Sportback 50 e-tron, Q8 Sportback 55 e-tron, e-tron GT, and RS e-tron GT, into the country.

Read More

​ The automaker currently imports its entire EV range comprising Q8 50 e-tron, Q8 55 e-tron, Q8 Sportback 50 e-tron, Q8 Sportback 55 e-tron, e-tron GT, and RS e-tron GT, into the country. The automaker currently imports its entire EV range comprising Q8 50 e-tron, Q8 55 e-tron, Q8 Sportback 50 e-tron, Q8 Sportback 55 e-tron, e-tron GT, and RS e-tron GT, into the country.  Moneycontrol Latest News Read More  

The automaker currently imports its entire EV range comprising Q8 50 e-tron, Q8 55 e-tron, Q8 Sportback 50 e-tron, Q8 Sportback 55 e-tron, e-tron GT, and RS e-tron GT, into the country.

Buy AU Small Finance Bank; target of Rs 720: Motilal Oswal

Buy AU Small Finance Bank; target of Rs 720: Motilal Oswal

Motilal Oswal is bullish on AU Small Finance Bank recommended buy rating on the stock with a target price of Rs 720 in its research report dated March 19, 2024.

Read More

​ Motilal Oswal is bullish on AU Small Finance Bank recommended buy rating on the stock with a target price of Rs 720 in its research report dated March 19, 2024. Motilal Oswal is bullish on AU Small Finance Bank recommended buy rating on the stock with a target price of Rs 720 in its research report dated March 19, 2024.  Moneycontrol Latest News Read More  

Motilal Oswal is bullish on AU Small Finance Bank recommended buy rating on the stock with a target price of Rs 720 in its research report dated March 19, 2024.

Song launch: Alan Walker Crafts Team Song For RCB Ahead Of IPL 2024

Song launch: Alan Walker Crafts Team Song For RCB Ahead Of IPL 2024

Titled ‘Team Side ft RCB’ and featuring pop artist Sofiloud, the sensational track will be premiered live by the EDM prodigy for the very first time at his 30-minute set at #RCBUnbox on March 19 at Bengaluru’s M Chinnaswamy Stadium.

Read More

​ Titled ‘Team Side ft RCB’ and featuring pop artist Sofiloud, the sensational track will be premiered live by the EDM prodigy for the very first time at his 30-minute set at #RCBUnbox on March 19 at Bengaluru’s M Chinnaswamy Stadium. Titled ‘Team Side ft RCB’ and featuring pop artist Sofiloud, the sensational track will be premiered live by the EDM prodigy for the very first time at his 30-minute set at #RCBUnbox on March 19 at Bengaluru’s M Chinnaswamy Stadium.  Moneycontrol Latest News Read More  

Titled ‘Team Side ft RCB’ and featuring pop artist Sofiloud, the sensational track will be premiered live by the EDM prodigy for the very first time at his 30-minute set at #RCBUnbox on March 19 at Bengaluru’s M Chinnaswamy Stadium.

en_USEnglish